| Current assets: |
| Cash and cash equivalents |
2.08B |
| Marketable securities |
| Accounts receivable, net |
1.47B |
| Due from unconsolidated joint business |
| Inventory |
1.01B |
| Other current assets |
993.1M |
| Total current assets |
8.09B |
| Marketable securities |
| Property, plant and equipment, net |
2.39B |
| Intangible assets, net |
3.87B |
| Goodwill |
3.42B |
| Investments and other assets |
1.24B |
| Total assets |
22.1B |
| Current liabilities: |
| Current portion of notes payable, line of credit and other financing arrangements |
| Taxes payable |
208.8M |
| Accounts payable |
274M |
| Accrued expenses and other |
2.01B |
| Total current liabilities |
2.5B |
| Notes payable and line of credit |
| Long-term deferred tax liability |
98.7M |
| Other long-term liabilities |
862.1M |
| Total liabilities |
9.99B |
| Commitments and contingencies (Notes 2, 11, 16, 18 and 20) |
0 |
| Biogen Idec Inc. shareholders' equity |
| Preferred stock, par value $0.001 per share |
0 |
| Common stock, par value $0.0005 per share |
100K |
| Additional paid-in capital |
0 |
| Accumulated other comprehensive income (loss) |
-300.9M |
| Retained earnings |
15.03B |
| Treasury stock, at cost |
-2.61B |
| Total Biogen Idec Inc. shareholders' equity |
12.12B |
| Noncontrolling interests |
-2.7M |
| Total equity |
12.11B |
| Total liabilities and equity |
22.1B |
